MSB

7.69%

$1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-606

First 606 Last

Share
Profile

Follow
hlinvest

136 Posts.

25

09/10/20

18:53

Post #: 47986702
Share

Originally posted by stockrock: ↑

In revisiting some announcements in 2018... I found something quite informative.

On the 22nd Feb 2018 MSB announced that they had met the primary endpoint for the phase 3 SR-aGVHD clinical trial. At that time they said this

”Based on interactions with the FDA, Mesoblast believes successful results from the completed phase 3 trial, together with Day 180 safety and quality of life parameters in these patients, may provide sufficient clinical evidence for filing for accelerated approval...”

This was reiterated in June 2018 when the 100 day survival data was strong and was to be presented at a conference.

Then on 20 Sep 2018, the 180 safety data was available and continued to show strong survival outcomes. At this point it appears management made a decision to go for full approval with priority review.

I can’t access the webcasts around that time, but that is when I recall Silviu being asked why they had not taken the accelerated approval pathway and he responded that they were very confident with full approval given the strength of the data in hand.

If someone has luck accessing that webcast, it would be good to have the accuracy of my recollection confirmed or clarified.

In any case, it appears the FDA and MSB has prior discussions on accelerated approval and the FDA may have even encouraged them to take that path... I say this because it sounds like the discussions were positive... but instead it appears management went for full approval instead.

This could partly explain the combative language/attitude the FDA conveyed in their briefing notes. Maybe a little annoyed MSB tried to overreach for full approval... when an accelerated pathway was available and they suggested MSB would be in a position to apply for such an expedited approval pathway.

This does alleviate some of my concern when it comes to the eligibility for accelerated approval, in that the data needs to be “adequate and well controlled” as well as the use of 28 ORR as surrogate data. It appears MSB already have guidance from the FDA on all of this.

What MSB have now is a successful phase 3 single arm trial, strong 180 day survival data... and a 9-1 ODAC vote. The ODAC vote probably puts it well beyond doubt that the data is considered “adequate and well controlled”.

Expand

I find it illogical that if the FDA suggested expedited pathway for approval and Mesoblast blatantly ignored it and went for full approval. After all ultimately the FDA is the one going to approve it. That just does not make sense, what else Mesoblast was going to add to the BLA that would persuade the FDA to change their mind ?

MSB Price at posting: $3.37 Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Bitcoin investors need to know the risks

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

There are more pages in this discussion • 412 more messages in this thread...

First 606 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.19		Change 0.085(7.69%)		Mkt cap ! $1.358B

Open	High	Low	Value	Volume
$1.10	$1.20	$1.09	$13.21M	11.37M

Buyers (Bids)

No.	Vol.	Price($)
1	15000	$1.19

Sellers (Offers)

Price($)	Vol.	No.
$1.19	75212	5

View Market Depth

No.	Vol.	Price($)
1	15000	1.185
1	20000	1.175
1	5664	1.170
1	17568	1.160
3	56695	1.150

Price($)	Vol.	No.
1.190	59712	2
1.195	36255	5
1.200	404381	31
1.205	3000	1
1.210	162475	7

Last trade - 16.10pm 12/07/2024 (20 minute delay)

MSB (ASX) Chart

MSB to dispute FDA finding in Type A meeting, page-606

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Immutep reports strong response rate from immunotherapies treating carcinomas

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB to dispute FDA finding in Type A meeting, page-606

Top Stories

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Immutep reports strong response rate from immunotherapies treating carcinomas

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News